Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acrivon Therapeutics Inc (ACRV)

Acrivon Therapeutics Inc (ACRV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,479
  • Shares Outstanding, K 31,555
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,560 K
  • EBIT $ -89 M
  • EBITDA $ -92 M
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.49
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -0.52
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +18.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5700 +26.11%
on 01/13/26
3.5600 -44.38%
on 01/07/26
-0.4400 (-18.18%)
since 12/16/25
3-Month
1.5700 +26.11%
on 01/13/26
3.5600 -44.38%
on 01/07/26
+0.1100 (+5.88%)
since 10/16/25
52-Week
1.0500 +88.57%
on 06/02/25
8.0000 -75.25%
on 02/05/25
-3.5700 (-64.32%)
since 01/16/25

Most Recent Stories

More News
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 1.0100 (+3.80%)
BCT.TO : 5.97 (-4.48%)
ACRV : 1.9800 (+5.88%)
LLY : 1,038.40 (+0.53%)
BCTX : 4.29 (-4.45%)
GLSI : 24.88 (-8.50%)
CATX : 2.33 (-6.05%)
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall...

ACRV : 1.9800 (+5.88%)
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 1.9800 (+5.88%)
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 1.9800 (+5.88%)
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 1.9800 (+5.88%)
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial...

ACRV : 1.9800 (+5.88%)
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development Favorable ACR-2316 preclinical...

ACRV : 1.9800 (+5.88%)
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 1.9800 (+5.88%)
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316...

ACRV : 1.9800 (+5.88%)
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

ACRV : 1.9800 (+5.88%)

Business Summary

Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform,...

See More

Key Turning Points

3rd Resistance Point 2.1867
2nd Resistance Point 2.1133
1st Resistance Point 2.0467
Last Price 1.9800
1st Support Level 1.9067
2nd Support Level 1.8333
3rd Support Level 1.7667

See More

52-Week High 8.0000
Fibonacci 61.8% 5.3451
Fibonacci 50% 4.5250
Fibonacci 38.2% 3.7049
Last Price 1.9800
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar